Q-omics provides the consensus-scored ARMCX5-GPRASP2 profile across patient tissues and cancer cell-line models. ARMCX5-GPRASP2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, ARMCX5-GPRASP2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, ARMCX5-GPRASP2 RNA expression shows 20,051 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, HNSC, and UVM as cancer lineages where ARMCX5-GPRASP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARMCX5-GPRASP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARMCX5-GPRASP2 survival associations across molecular data types. ARMCX5-GPRASP2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARMCX5-GPRASP2 RNA expression–survival associations across cancer types. High ARMCX5-GPRASP2 expression shows unfavorable associations in KICH, UVM, KIRP and LIHC, but favorable associations in UCS and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for ARMCX5-GPRASP2 RNA expression.
This table summarizes ARMCX5-GPRASP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ARMCX5-GPRASP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARMCX5-GPRASP2 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in HNSC, LIHC and CHOL. The HNSC box plot shows higher ARMCX5-GPRASP2 RNA expression in tumor versus normal tissue (log2 FC = +0.465, t-test p < 0.001).
This table shows molecular features associated with ARMCX5-GPRASP2 in patient tissues and cancer cell lines. In patient samples, ARMCX5-GPRASP2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARMCX5-GPRASP2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
